Using a different algorithm to predict immunogenic neoantigens, Duan et al. showed that vaccination against a neoepitope within Tnpo3 induced tumor regression in a prophylactic setting, and combination therapy with anti-CD25 or anti-CTLA4 improved the response to neoantigen vaccination (26). The gene discussed is CTLA4; the disease is neoplasm.